Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
585.23(c) 587.24(c) 583.72(c) 586.88(c) 586.35(c) Last
552 105 644 953 480 841 406 910 626 463 Volume
+0.34% +0.34% -0.60% +0.54% -0.09% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 12 231 M - -
Net income 2021 4 984 M - -
Net cash position 2021 9 191 M - -
P/E ratio 2021 12,5x
Yield 2021 -
Sales 2022 11 250 M - -
Net income 2022 4 047 M - -
Net cash position 2022 10 760 M - -
P/E ratio 2022 15,0x
Yield 2022 -
Capitalization 60 720 M 60 720 M -
EV / Sales 2021 4,21x
EV / Sales 2022 4,44x
Nbr of Employees 9 447
Free-Float 82,2%
More Financials
Company
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis,... 
More about the company
Ratings of Regeneron Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about REGENERON PHARMACEUTICALS
07/23REGENERON PHARMACEUTICALS : RBC Raises Price Target on Regeneron Pharmaceuticals..
MT
07/20Agilent Technologies PharmDx Assay Receives Expanded Use in EU
MT
07/20REGENERON PHARMACEUTICALS : Antibody Cocktail Gets Full Approval in Japan as Tre..
MT
07/20REGENERON PHARMACEUTICALS : Japan Becomes First Country to Approve Regeneron Ant..
PR
07/19Roche's Ronapreve Treatment for Covid-19 Approved by Japan
DJ
07/19Chugai Pharmaceutical Obtains Approval for Covid Antibody Cocktail
DJ
07/19EU evaluates Sobi arthritis drug to treat COVID-19 with pneumonia
RE
07/16REGENERON PHARMACEUTICALS : Plans $1.8 Billion Expansion in Westchester County, ..
MT
07/16REGENERON PHARMACEUTICALS : AbbVie, Lilly face fresh delays in FDA approval for ..
RE
07/13GSK-Vir Biotechnology's COVID-19 Antibody Wins Distribution Nod in Italy
MT
07/13ISA Pharmaceuticals B.V. announced that it has received €26 million in fundin..
CI
07/08REGENERON PHARMACEUTICALS : Benchmark Capital Adjusts Regeneron Pharmaceuticals ..
MT
07/07REGENERON PHARMACEUTICALS : to Report Second Quarter 2021 Financial and Operatin..
PR
07/07INSIDER TRENDS : Insider at Regeneron Pharmaceuticals Converts/Exercises Derivat..
MT
07/07SILVERBACK THERAPEUTICS : Signs Supply Deal With Regeneron for Libtayo in Early-..
MT
More news
News in other languages on REGENERON PHARMACEUTICALS
07/20Résumé des principales informations économiques du mardi 20 juillet 2021
07/20PLANÈTE BOURSE : La revue de presse du mardi 20 juillet 2021
07/20Roches Covid-19-Medikament Ronapreve erhält Zulassung in Japan
07/20Roche obtient un feu vert au Japon pour son cocktail anti-Covid
07/20ROCHE : Japan lässt als erstes Land Covid-Medikamentencocktail zu
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 586,35 $
Average target price 638,39 $
Spread / Average Target 8,88%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS21.37%57 013
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308
BEIGENE, LTD.22.66%33 627